journal
MENU ▼
Read by QxMD icon Read
search

Clinical Research in Cardiology Supplements

journal
https://www.readbyqxmd.com/read/28717887/erratum-to-the-german-lipoprotein-apheresis-registry-glar-almost-5%C3%A2-years-on
#1
V J J Schettler, C L Neumann, C Peter, T Zimmermann, U Julius, E Roeseler, F Heigl, P Grützmacher, H Blume, A Vogt
No abstract text is available yet for this article.
July 17, 2017: Clinical Research in Cardiology Supplements
https://www.readbyqxmd.com/read/28236286/editorial-lp-a-the-underestimated-cardiovascular-risk-factor
#2
EDITORIAL
Klaus-Peter Mellwig
No abstract text is available yet for this article.
March 2017: Clinical Research in Cardiology Supplements
https://www.readbyqxmd.com/read/28233270/lipoprotein%C3%A2-a-and-coronary-heart-disease-is-there-an-efficient-secondary-prevention
#3
Klaus-Peter Mellwig, Dieter Horstkotte, Frank van Buuren
Lipoprotein (a) (Lp (a)) is one risk factor for the development of cardiovascular diseases. Several studies have shown that Lp (a) hyperlipoproteinaemia has a particular influence on the development of coronary heart disease (CHD). A retrospective single-centre observation study was performed to evaluate the effectiveness of lipid apheresis on the basis of consecutively performed percutaneous coronary interventions (PCI) in patients with high Lp (a) values and angiographically documented CHD.In 23 pts (male 18, age 60...
March 2017: Clinical Research in Cardiology Supplements
https://www.readbyqxmd.com/read/28233269/primary-and-secondary-prevention-of-cardiovascular-disease-in-patients-with-hyperlipoproteinemia%C3%A2-a
#4
REVIEW
P Grützmacher, B Öhm, S Szymczak, C Dorbath, M Brzoska, C Kleinert
General lipoprotein (Lp) (a) screening can help to identify patients at high risk for cardiovascular disease. Non-invasive methods allow early detection of clinically asymptomatic incipient atherosclerotic disease. Medical treatment options are still unsatisfactory. Lp(a) apheresis is an established treatment in Germany for secondary prevention of progressive cardiovascular disease. Statin-based lowering of LDL cholesterol and thrombocyte aggregation inhibitors still represent the basis of medical treatment...
March 2017: Clinical Research in Cardiology Supplements
https://www.readbyqxmd.com/read/28233268/the-german-lipoprotein-apheresis-registry-glar-almost-5%C3%A2-years-on
#5
V J J Schettler, C L Neumann, C Peter, T Zimmermann, U Julius, E Roeseler, F Heigl, P Grützmacher, H Blume, A Vogt
BACKGROUND: Since 2005 an interdisciplinary German apheresis working group has been established by members of both German Societies of Nephrology and of Lipidologists and completed the data set for the registry according to the current guidelines and the German indication guideline for apheresis in 2009. In 2011 the German Lipoprotein Apheresis Registry (GLAR) was launched and data are available over nearly 5 years now. METHODS AND RESULTS: During the time period 2012-2016, 71 German apheresis centers collected retrospective and prospective observational data of 1435 patients undergoing lipoprotein apheresis (LA) treatment of high LDL-C levels and/or high Lp (a) levels suffering from cardiovascular disease (CVD) or progressive CVD...
March 2017: Clinical Research in Cardiology Supplements
https://www.readbyqxmd.com/read/28229283/incidence-of-elevated-lipoprotein%C3%A2-a-levels-in-a%C3%A2-large-cohort-of-patients-with-cardiovascular-disease
#6
Frank van Buuren, Dieter Horstkotte, Cornelius Knabbe, Dennis Hinse, Klaus Peter Mellwig
BACKGROUND: Recently it has been demonstrated that elevated lipoprotein (a) (LPA) levels are associated with an increased risk of cardiovascular disease across multiple ethnic groups. However, there is only scanty data about the incidence of elevated LPA levels in different patient cohorts. As a consequence, we aimed to examine whether patients with elevated LPA levels might be seen more often in a cardiovascular center in comparison to the general population. METHODS: We reviewed LPA concentrations of 52,898 consecutive patients who were admitted to our hospital between January 2004 and December 2014...
March 2017: Clinical Research in Cardiology Supplements
https://www.readbyqxmd.com/read/28188431/lipoprotein-a-and-its-role-in-inflammation-atherosclerosis-and-malignancies
#7
Evelyn Orsó, Gerd Schmitz
Lipoprotein (a) (Lp(a)) is a modified low-density lipoprotein (LDL) particle with an additional specific apolipoprotein (a), covalently attached to apolipoprotein B‑100 of LDL by a single thioester bond. Increased plasma Lp(a) level is a genetically determined, independent, causal risk factor for cardiovascular disease.The precise quantification of Lp(a) in plasma is still hampered by mass-sensitive assays, large particle variation, poor standardization and lack of assay comparability.The physiological functions of Lp(a) include wound healing, promoting tissue repair and vascular remodeling...
March 2017: Clinical Research in Cardiology Supplements
https://www.readbyqxmd.com/read/28185214/prevention-of-cardiovascular-complications-in-patients-with-lp-a-hyperlipoproteinemia-and-progressive-cardiovascular-disease-by-long-term-lipoprotein-apheresis-according-to-german-national-guidelines
#8
MULTICENTER STUDY
Reinhard Klingel, Andreas Heibges, Cordula Fassbender
Lipoprotein(a) (Lp(a)) is an independent cardiovascular risk factor playing a causal role for atherosclerotic cardiovascular disease (CVD). Lipoprotein apheresis (LA) is a safe well-tolerated outpatient treatment to lower LDL-C and Lp(a) by 60-70%, and is the ultimate escalating therapeutic option in patients with hyperlipoproteinemias (HLP) involving LDL particles. Major therapeutic effect of LA is preventing cardiovascular events. Lp(a)-HLP associated with progressive CVD has been approved as indication for regular LA in Germany since 2008...
March 2017: Clinical Research in Cardiology Supplements
https://www.readbyqxmd.com/read/28185213/hyperlipoproteinaemia-a-apheresis-and-emerging-therapies
#9
REVIEW
Anja Vogt
A high level of lipoprotein(a) (Lp(a)) is recognized as an independent and additional cardiovascular risk factor contributing to the risk of early onset and progressive course of cardiovascular disease (CVD). All lipid lowering medications in use mainly lower low density lipoprotein-cholesterol (LDL-c) with no or limited effect on levels of Lp(a). Niacin, the only component lowering Lp(a), is firstly often poorly tolerated and secondly not available anymore in many countries. A level of <50 mg/dl was recommended recently as the cut off level for clinical use and decision making...
March 2017: Clinical Research in Cardiology Supplements
https://www.readbyqxmd.com/read/28181057/lipoprotein-a-in-nephrological-patients
#10
REVIEW
Bernd Hohenstein
In contrast to existing EAS/ESC guidelines on the management of lipid disorders, current recommendations from nephrological societies are very conservative and restrictive with respect to any escalation of lipid lowering/statin therapy. Furthermore, lipoprotein(a) (Lp(a)) - an established cardiovascular risk factor - has not even been mentioned. While a number of retrospective and prospective studies suggested that Lp(a) has relevant predictive value and might have - at least in stage-3 chronic kidney disease (CKD) - the same negative effects if draged along in non-CKD patients, there is no guidance on diagnostic or therapeutic procedures...
March 2017: Clinical Research in Cardiology Supplements
https://www.readbyqxmd.com/read/28176216/pcsk9-targets-important-for-lipid-metabolism
#11
REVIEW
Rainer Schulz, Klaus-Dieter Schlüter
Ischemic heart disease is the main cause of death worldwide and it is accelerated by increased low-density lipoprotein (LDL) cholesterol (LDL-C) and/or lipoprotein (a) (Lp(a)) concentrations. Proprotein convertase subtilisin/kexin type 9 (PCSK9) alters both LDL-C and in part Lp(a) concentrations through its ability to induce degradation of the LDL receptor (LDLR). PCSK9, however, has additional targets which are potentially involved in lipid metabolism regulation such as the very low density lipoprotein receptor (VLDL), CD36 (cluster of differentiation 36) and the epithelial cholesterol transporter (NPC1L1) and it affects expression of apolipoprotein B48...
March 2017: Clinical Research in Cardiology Supplements
https://www.readbyqxmd.com/read/28160245/lipoprotein-a-hyperlipoproteinemia-as-cause-of-chronic-spinal-cord-ischemia-resulting-in-progressive-myelopathy-successful-treatment-with-lipoprotein-apheresis
#12
Franz Heigl, Reinhard Hettich, Erich Mauch, Reinhard Klingel, Cordula Fassbender
High concentrations of lipoprotein(a) (Lp(a)) represent an important independent and causal risk factor associated with adverse outcome in atherosclerotic cardiovascular disease (CVD). Effective Lp(a) lowering drug treatment is not available. Lipoprotein apheresis (LA) has been proven to prevent cardiovascular events in patients with Lp(a)-hyperlipoproteinemia (Lp(a)-HLP) and progressive CVD. Here we present the course of a male patient with established peripheral arterial occlusive disease (PAOD) at the early age of 41 and coronary artery disease (CAD), who during follow-up developed over 2 years a progressive syndrome of cerebellar and spinal cord deficits against the background of multifactorial cardiovascular risk including positive family history of CVD...
March 2017: Clinical Research in Cardiology Supplements
https://www.readbyqxmd.com/read/26882905/-rehabilitation-standards-for-follow-up-treatment-and-rehabilitation-of-patients-with-ventricular-assist-device-vad
#13
REVIEW
Detlev Willemsen, C Cordes, B Bjarnason-Wehrens, E Knoglinger, E Langheim, R Marx, N Reiss, T Schmidt, A Workowski, P Bartsch, C Baumbach, C Bongarth, H Phillips, R Radke, M Riedel, S Schmidt, E Skobel, C Toussaint, J Glatz
The increasing use of ventricular assist devices (VADs) in terminal heart failure patients provides new challenges to cardiac rehabilitation physicians. Structured cardiac rehabilitation strategies are still poorly implemented for this special patient group. Clear guidance and more evidence for optimal modalities are needed. Thereby, attention has to be paid to specific aspects, such as psychological and social support and education (e.g., device management, INR self-management, drive-line care, and medication)...
March 2016: Clinical Research in Cardiology Supplements
https://www.readbyqxmd.com/read/26882904/-not-available
#14
EDITORIAL
Hermann Reichenspurner
No abstract text is available yet for this article.
March 2016: Clinical Research in Cardiology Supplements
https://www.readbyqxmd.com/read/25732622/lipoprotein-a-clinical-aspects-and-future-challenges
#15
Bilgen Kurt, Muhidien Soufi, Alexander Sattler, Juergen R Schaefer
Lipoprotein(a) (Lp(a)) was first described by K. Berg and is known for more than 50 years. It is an interesting particle and combines the atherogenic properties of low-density lipoprotein (LDL)-cholesterol as well as the thrombogenic properties of plasminogen inactivation. However, due to technical problems and publication of negative trials the potential role of Lp(a) in atherosclerosis was severely underestimated. In recent years our understanding of the function and importance of Lp(a) improved. Interventional trials with niacin failed to demonstrate any benefit of lowering Lp(a); however, several studies confirmed the residual cardiovascular disease (CVD) risk of elevated Lp(a)...
April 2015: Clinical Research in Cardiology Supplements
https://www.readbyqxmd.com/read/25708587/lipoprotein-a-hyperlipidemia-as-cardiovascular-risk-factor-pathophysiological-aspects
#16
Gerd Schmitz, Evelyn Orsó
Lipoprotein (a) [Lp(a)] is a modified LDL particle with an additional apolipoprotein [apo(a)] protein covalently attached by a thioester bond. Multiple isoforms of apo(a) exist that are genetically determined by differences in the number of Kringle-IV type-2 repeats encoded by the LPA gene. Elevated plasma Lp(a) is an independent risk factor for cardiovascular disease.The phenotypic diversity of familial Lp(a) hyperlipidemia [Lp(a)-HLP] and familial hypercholesterolemia [FH], as defined risks with genetic background, and their frequent co-incidence with additional cardiovascular risk factors require a critical revision of the current diagnostic and therapeutic recommendations established for isolated familial Lp(a)-HLP or FH in combination with elevated Lp(a) levels...
April 2015: Clinical Research in Cardiology Supplements
https://www.readbyqxmd.com/read/25690176/-editorial
#17
EDITORIAL
Dieter Horstkotte
No abstract text is available yet for this article.
April 2015: Clinical Research in Cardiology Supplements
https://www.readbyqxmd.com/read/25686595/indications-for-apheresis-as-an-ultima-ratio-treatment-of-refractory-hyperlipidemias
#18
P Grützmacher, C Kleinert, C Dorbath, B Öhm
Lipid apheresis is at present well established in routine treatment of diverse hyperlipoproteinemias refractory to conventional dietary and medical regimens, especially in countries with high medical and socioeconomic standards. Severe familial hypercholesterolemia with atherosclerotic vessel disease involving the coronary arteries is the most frequent indication for lipid apheresis as well as homozygous familial hypercholesterolemia before the development of cardiovascular complications.In hyperlipoproteinemia (a) with progressive vessel disease, lipid apheresis is regularly accepted in Germany...
April 2015: Clinical Research in Cardiology Supplements
https://www.readbyqxmd.com/read/25672934/clinical-benefit-of-long-term-lipoprotein-apheresis-in-patients-with-severe-hypercholesterolemia-or-lp-a-hyperlipoproteinemia-with-progressive-cardiovascular-disease
#19
Franz Heigl, Reinhard Hettich, Norbert Lotz, Harduin Reeg, Tobias Pflederer, Dirk Osterkorn, Klaus Osterkorn, Reinhard Klingel
Low-density lipoprotein cholesterol (LDL-C) and lipoprotein(a) (Lp(a)) are established causal risk factors for cardiovascular disease (CVD). Efficacy, safety, and tolerability of lipoprotein apheresis (LA) were investigated in 118 patients with CVD covering a period with 36,745 LA treatments in a retrospective, monocentric study. Indications for LA were severe hypercholesterolemia (n = 83) or isolated Lp(a) hyperlipoproteinemia (Lp(a)-HLP) (n = 35). In patients with hypercholesterolemia, initial pre-LA LDL-C was 176...
April 2015: Clinical Research in Cardiology Supplements
https://www.readbyqxmd.com/read/25666917/-lipoprotein-a-influence-on-cardiovascular-manifestation
#20
K-P Mellwig, C Schatton, B Biermann, T Kottmann, D Horstkotte, F van Buuren
The clinical relevance of lipoprotein(a) (Lp(a)) as a cardiovascular risk factor is currently underestimated. The aim of our study was to assess the influence of increased Lp(a) values on the development and severity of coronary artery disease (CAD).In our retrospective analysis of 31,274 patients, who were hospitalized for the first time, we compared patients with isolated increased Lp(a) (> 110 mg/dl) and normal Lp(a) (< 30 mg/dl), with increased Lp(a) concentrations (30-60 mg/dl, 61-90 mg/dl, 91-110 mg/dl), and in a third analysis with additionally increased LDL cholesterol and HbA1c values...
April 2015: Clinical Research in Cardiology Supplements
journal
journal
43221
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"